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ABSTRACT 
The ability to perform endurance exercise is dependent on the transport of oxygen to the active 
skeletal muscles. For oxygen to perfuse into the skeletal muscle, flexibility of red blood cells is 
crucial in determining the passage through narrow capillaries, thus the erythrocytes must deform 
to increase regional blood flow through the microvasculature.  It has been shown at submaximal 
exercise and in conditions of acute hypoxia, erythrocyte deformability is decreased, however 
supplementation of omega-3 polyunsaturated fatty acids (PUFAs) has been shown to increase 
erythrocyte deformability. PURPOSE: The purpose of this study is to determine the effects of 
chronic omega-3 fatty acid supplementation on erythrocyte deformability and tissue oxygenation 
in highly trained cyclists during submaximal exercise in both normoxic and hypoxic conditions. 
METHODS: The protocol was performed on thirteen highly trained cyclists (VO2 max 
≥55ml/kg/min). The subjects were divided into treatment (2g of DHA, 3g of EPA, and 100mg of 
Vitamin E) and placebo (safflower oil) groups. The subjects’ visits pre- and post-
supplementation followed identical protocols with one visit occurring in normoxia and the other 
in acute hypoxia (FIO2 =15%). Each visit involved 2 submaximal cycling bouts of 3 minutes, 
equaling 25% and 50% of peak power, and one bout at 75% of peak power to exhaustion. 
Erythrocyte elongation index (EI) and near infrared spectroscopy (NIRS) measures were 
recorded for each trial. RESULTS: There were no significant differences in Elongation Index 
(EI) when comparing baseline values to measurements taken post-exercise in the hypoxic 
condition prior to supplementation. After supplementation, there were no significant differences 
in baseline EI when compared to pre-supplementation values. After the hypoxic exercise trial, EI 
at 20 Pa of shear stress was significantly greater within the PUFA group post-supplementation 
(pre: 0.574 ± 0.004; post: 0.580 ± 0.003; p<0.05).EI at 20 Pa was significantly greater post-
supplementation in the PUFA group compared to the placebo group (PUFA: 0.580 ± 0.003; 
placebo: 0.574 ± 0.006; p<0.05).There were no significant difference in any of the NIRS 
measures any common workload CONCLUSION:   Erythrocye deformability did not decrease 
with exercise in hypoxia, nor did baseline levels change with omega-3 supplementation, and 
only a marginal significant difference on post-exercise erythrocyte deformability measures was 
demonstrated. There was no effect on microvascular tissue oxygenation measures. 
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CHAPTER 1: INTRODUCTION 
 
The ability to perform endurance exercise is dependent on the transport of oxygen 
through the vasculature and the perfusion of oxygen into the active skeletal muscles. This relies 
on the capability of the oxygen-carrying erythrocytes to reach the appropriate tissues.  As 
regional blood flow increases, blood perfuses into the microvasculature, which can be as narrow 
as 3 m in diameter[1]. Since erythrocytes are, on average, 7m in diameter, the tissues supplied 
by the microvasculature rely on the ability of erythrocytes to deform for the delivery of oxygen 
[2]. In cases where the erythrocytes are unable to adequately deform, they bypass the most 
narrow vessels of the microvasculature [3], thus causing areas of skeletal muscle to lack 
adequate oxygenation. There are a variety of conditions where erythrocyte deformability is 
reduced, and there are a number of factors that influence these changes. It has been suggested 
that decreased intracellular ATP, as well as decreased arterial hemoglobin saturation could 
decrease deformability [4, 5] such as during submaximal exercise [3] and at altitude [6]. In these 
cases, the delivery of oxygen to active tissues may be limited, and (if so) consequently the ability 
to perform endurance exercise would be reduced.    
In the cases of submaximal exercise and acute hypoxia, blood flow is increased to regions 
of active tissue [3], however the decrease of erythrocyte deformability at these same conditions 
may prevent the maximal effects of these adaptations. In order for maximal oxygen delivery to 
occur in the active skeletal muscle, erythrocyte deformability must be maintained to allow for 
passage through the microvasculature. Changes occurring in erythrocyte deformability have been 
investigated in the effects of various diseases states[1, 7], drugs, varying levels of physical 
activity[8], and environmental conditions[3, 9-11]. It has been shown that erythrocyte 
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deformability is higher in elite athletes than untrained controls [8], however the research 
exploring the effect of erythrocyte deformability on microvascular oxygen delivery in highly 
trained individuals has not been extensively pursued.  
Purpose of the study 
 
There are three factors that influence whether erythrocytes maintain adequate 
deformability for transport through the microvasculature: 1) the biconcave shape, resulting in the 
high surface area-to-volume ratio of the cell, 2) the viscoelastic properties of the cell membrane, 
and 3) the viscosity of the hemoglobin solution within the cell [1].  In regards to the viscoelastic 
properties of the cell membrane, a correlation has been demonstrated in the literature between 
erythrocyte deformability and phospholipid content in the cell membrane[12]. This suggests that 
by increasing the phospholipid content in the lipid bilayer of the red cell membrane, erythrocyte 
deformability could be improved, and therefore oxygenation of tissues supplied by the 
microvasculature could increase. 
Omega-3 polyunsaturated fatty acids (PUFAs) are a phospholipid whose clinical 
properties have been investigated extensively[1]. It has been demonstrated that chronic 
supplementation of PUFAs increases erythrocyte deformability and skeletal muscle blood flow 
[13]. However, whether any omega-3 mediated increase in erythrocyte deformability leads to 
improvements in microvascular oxygenation during exercise and/or hypoxic exposure is not 
known. The purpose of this study is to determine the effects of chronic omega-3 fatty acid 
supplementation on erythrocyte deformability and tissue oxygenation in highly trained cyclists 
during submaximal exercise in both normoxic and hypoxic conditions.  The aim is to establish a 
possible method for attenuating the current limitation of erythrocyte deformability to exercise in 
elite athletes in both normoxic and hypoxic conditions. 
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Hypotheses 
 
1. Erythrocyte deformability will decrease from rest after hypoxic submaximal 
exercise 
2. After chronic omega-3 PUFA supplementation (versus placebo), erythrocyte 
deformability will increase from pre-supplementation values 
3. Microvascular oxygen delivery and oxygen extraction (as assessed by near-
infrared spectroscopy) will increase in highly trained cyclists during submaximal 
exercise in both normoxia and hypoxia. 
 No changes in erythrocyte deformability or microvascular oxygenation are expected for those 
given the placebo treatment.  
Delimitations 
 
This study was delimited to the following: 
1. Fifteen trained cyclists with a VO2 max ≥ 55mL/kg
/
min. 
2. The inspirate for experimental trials (normoxia or hypoxia) was randomized and 
blinded for each subject. 
3. Subjects were blinded and randomized into placebo and supplementation groups 
4. Subjects were required to make five visits to the lab: a preliminary graded 
maximal exercise(VO2 max) test, two pre-tests in both normoxia and hypoxia, and 
two post-tests in both normoxia and hypoxia 
5. Subjects performed each of the five trials at the same time of day. 
Limitations 
 
The results of this study were interpreted with the following limitations:  
4 
 
1. Subjects were selectively chosen to be highly trained. 
2. The procedure followed subjects in the lab with a facemask attached during 
exercise, which is noticeably different than the usual training for athletes. 
3. Trial took place with subjects while breathing inspirate with reduced oxygen 
levels (normobaric hypoxia), which is markedly different from 
competition/training these athletes may undergo at altitude (hypobaric hypoxia). 
4. The findings from this study can only be attributed to a moderate altitude of 
approximately 3000m. 
Assumptions 
 
This study was based on the following assumptions: 
1. Subjects accurately represented highly trained individuals. 
2. Subjects did not change training status while undergoing testing. 
3. Subjects followed treatment directions by ingesting the required daily dosage for 
the entire 6 weeks of supplementation. 
4. Simulated altitude correlates with actual altitude. 
Definitions 
 
Erythrocyte Deformability: the physical characteristics of a red blood cell that permit it to change 
shape when under pressure, such as is required in the microcirculation. 
Elongation Index: A measure of erythrocyte deformability.  
Normoxia: Inspired air with an oxygen content of 0.2093 
Hypoxia: Inspired air with an oxygen content less than 0.2093 
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Arterial hemoglobin oxygen saturation (SaO2): The percentage of available hemoglobin binding 
oxygen. 
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CHAPTER 2: REVIEW OF LITERATURE 
Oxygen Delivery to Skeletal Muscle during Exercise 
The ability to perform endurance exercise is dependent on the transport of oxygen to the 
active skeletal muscles. It has been shown that the inability to increase oxygen delivery with 
increasing demand in locomotor muscles results in a limitation to aerobic capacity [14]. Bangsbo 
et al [15] investigated whether oxygen availability limits muscle oxygen uptake in the initial 
phase of intense exercise during a 3 minute bout of knee-extensor exercise. They found a delay 
in oxygen uptake after the onset of exercise, despite adequate oxygen delivery, as demonstrated 
in figure 1. The source of these limitations is suggested to be the misdistribution of blood flow in 
the exercising muscles limits, and not the transport of blood to the active tissues[15, 16]. 
 
Figure 1. Difference between thigh oxygen delivery and thigh VO2 during a three minute knee extensor 
exercise bout[15] 
 
 
Upon the onset of skeletal muscle activity, blood flow increases rapidly. As the flow 
increases to the active tissue, additional capillary recruitment occurs, and blood perfuses into the 
microvasculature[17]. However, muscle capillary diameter is not greatly altered with increasing 
perfusion, therefore the oxygen-carrying erythrocytes must deform to allow for entry into the 
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microvasculature and the resulting appropriate distribution of increased blood flow to the 
tissue[18]. 
Erythrocyte Deformability 
 
Erythrocyte deformability is the physical characteristics which permit a red blood cell, 
whose greater diameter normally exceed 7 µ, to travel through capillaries as narrow as 3 µ in 
diameter, and is thus an essential part in the delivery of oxygen to the tissues [1]. Within the 
narrow capillaries, the flexibility of erythrocytes is the most important determinant of blood flow 
to the tissue [2]. Alterations in these intrinsic properties of erythrocytes interfere with blood flow 
through the microcirculation [19]. Three factors have been discussed in contributing to the 
deformability of a red blood cell: 1) the biconcave shape, resulting in the high surface area-to-
volume ratio of the cell, 2) the viscoelastic properties of the cell membrane, and 3) the viscosity 
of the hemoglobin solution within the cell [1].  
 
Figure 2. Video micrograph of an erythrocyte before and after entry into a small capillary [20]. 
 
The existing literature on erythrocyte deformability reports measurements from various 
techniques. One method commonly seen in the literature is erythrocyte filtration, which is 
defined by the ability of red blood cells to pass through a filter and is measured either by the time 
required for passage of a certain volume, or the volume of blood filtered in one minute[21]. The 
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filtration method passes a volume of blood through a membrane filter using a negative pressure, 
as seen in figure 3.  The flow of blood through the apparatus is strongly influenced by the   
deformability of the erythrocytes as the diameter of the pores in the filter is less than that of a 
single red blood cell[21]. 
 
Figure 3. Apparatus for erythrocyte filtration used by Reid et al.[21] 
Laser diffraction ellipsometry, or ektacytometry, is another frequently used method of 
measuring erythrocyte deformability. The erythrocytes are deformed to an ellipsoid shape and 
diffract a laser beam which passes through the test suspension and read by a detector, giving a 
measure of the elongation of the erythrocytes under a given shear stress[22], as demonstrated in 
figure 4. This method has demonstrated reproducibility, high precision, and narrow interassay 
variation[1]. 
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Figure 4. Changes in Elongation Index with increasing shear stress [23] 
 
Research involving changes occurring in erythrocyte deformability has been conducted in 
many areas, including various diseases states[1, 7], the effect of drugs[1], varying levels of 
physical activity[8] and environmental conditions[3, 9-11].  For the purpose of this review, the 
focus was on how omega-3 Poly Unsaturated Fatty Acids (PUFA) supplementation, and hypoxia 
can elicit changes in erythrocyte deformability.  
Omega-3 Polyunsaturated Fatty Acids 
Following dietary supplementation with omega-3 Poly Unsaturated Fatty Acids (PUFA) 
containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) , an increase in 
erythrocyte deformability [12, 13, 24], reduction in RBC aggregation [25], and reduced whole 
blood viscosity [13] has been demonstrated. Due to the positive correlation between erythrocyte 
deformability and EPA content in erythrocytes elastic properties of RBC membrane dependent 
on proportion of EPA [12], and therefore it is suggested that the supplementation with omega-3s 
target the viscoelastic properties of the erythrocyte membrane to increase deformability. 
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The effects of PUFA supplementation on erythrocyte deformability and blood viscosity 
in healthy subjects was studied by Terano et al [12]. After four weeks of supplementation with a 
daily dosage of 3.6g EPA, they found a decrease in whole blood and red cell viscosity, and an 
increase in erythrocyte deformability. They also demonstrated a correlation between 
deformability and phospholipid content in the red cell membrane, as seen in figure 5. This 
finding supports the notion that the increase in deformability with PUFA supplementation is due 
to an increase in the viscoelastic properties of the cell membrane. 
 
Figure 5. Correlation between erythrocyte deformability and EPA content in the red cell membrane.[12] 
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Cartwright et al [13]  also investigated the effects of PUFA supplementation on 
erythrocyte deformability and blood viscosity in healthy subjects. A total of 3.4g of omega-3 
were ingested each day, for a six week supplementation period. Test for erythrocyte 
phospholipid content, plasma and whole blood viscosity, and erythrocyte deformability were 
performed at 0, 3 and 6 weeks. An increase in filtration rate, indicating an increase in 
deformability, was seen at both three and six weeks, compared to baseline levels, as seen in 
figure 6. The analysis of erythrocyte phospholipids indicated an increase in membrane 
phospholipids after 6 weeks of supplementation with omega-3 PUFAs[13]. 
 
Figure 6. Changes in Red Cell Filtration Rate over the course of a six week PUFA supplementation 
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Due to the improvement in hematological factors, there have been attempts to 
demonstrate an increase in exercise performance with omega-3 supplementation [23]. It has been 
shown that erythrocyte deformability is higher in elite athletes than untrained controls [8], but 
the research on changes in deformability in highly trained individuals is currently limited. 
Oostenbrug et al. investigated the effects of PUFA supplementation on time trial performance in 
trained cyclists [12]. Although no improvement in performance was detected, no significant 
difference in erythrocyte deformability was demonstrated either, which is conflicting with 
previous findings. This could be due to a shortened supplementation time of only three weeks, 
where previous literature utilizes supplementation lengths of 4-12 weeks [12, 25], as well as a 
daily supplementation that totaled less than half the dosage of EPA used by Terano et al. 
It  has also been indicated that supplementation with PUFAs could result in an increase in 
VO2 max [26]. A recent pilot study has found only one of 106 German elite winter athletes to be 
in the target range for the HS-Omega-3 Index , which is the percentage of the two omega-3 fatty 
acids (EPA) and (DHA) in total erythrocyte fatty acids [27], demonstrating the possibility of a 
strong impact on research involving the effects of PUFA supplementation on erythrocyte 
deformability in elite athletes by targeting membrane phospholipid content. 
Hypoxia 
Decreases in erythrocyte deformability produced by hypoxia have been demonstrated 
both in vitro [28] and in vivo [11]. Not only does erythrocyte deformability decrease with 
hypoxia, but these resulting changes in the red blood cells have been found to compromise the 
ability to perfuse the additional capillary recruitment that ordinarily results from hypoxia [3]. 
Through indicatory dilution techniques and transit time measures in the rat cremaster muscle, 
Parthasarathi and Lipowsky demonstrated that erythrocytes with decreased deformability 
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followed more central flow pathways, as opposed to perfusing the increased capillary 
recruitment within the microvasculature that was shown to occur with hypoxia [3]. 
 To investigate how deformability is affected in hypoxia during exercise, Guezennec et al 
tested the effects of PUFA supplementation on physically trained subjects. The subjects 
performed 1 hour of exercise at 70% of VO2 Max in both normoxic and hypoxic conditions. This 
test was performed both before and after 6 weeks of supplementation with 6g of PUFAs daily. 
As seen in figure 7, index of filtration increases in hypoxia and with submaximal exercise, but 
these differences are reduced with PUFA supplementation. It should be noted that index of 
filtration is a measure that increases as erythrocyte deformability decreases. These results 
demonstrated a decrease in deformability with exercise at hypoxia, and an attenuation of this 
decrease in deformability with PUFA supplementation [6]. 
 
Figure 7. Changes in Filtration Index Pre- and Post- PUFA supplementation in normoxia (solid line) and hypoxia 
(dashed line) 
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Near Infrared Spectroscopy (NIRS)  
NIRS is a method in which skeletal muscle oxygenation can be monitored noninvasively 
during exercise [29]. Near infrared spectroscopy (NIRS) is a technique which a near infrared 
light is emitted from source, which travels through tissue, then the wavelength of the light 
returning to the detector  is measured, as demonstrated in figure 8.  
 
Figure 8. Schematic of method of action of NIRS[30] 
 
NIRS takes advantage of the ability of near-infrared light to be absorbed by both the 
oxygenated and deoxygenated hemoglobin (Hb) in erythrocytes, and myoglobin (Mb) in skeletal 
muscle. The varying wavelengths at which these proteins absorb near infrared light allows NIRS 
to distinguish between the Oxy-Hb and Oxy-Mb, and the resulting measurements have been 
shown to be sensitive to dynamic trends in muscle oxygen delivery and intracellular O2 
availability in humans[31]. NIRS has been compared with measurements of femoral vein blood 
gases and appeared to show a similar pattern of muscle dexoygenation during exercise [32]. The 
technology has allowed for further investigation into the mechanisms regulating regional tissue 
blood flow [33], and has demonstrated consistent pattern in the rate of decrease in muscle 
oxygenation during incremental exercise [34]. By measuring hemoglobin levels in the active 
skeletal muscles, NIRS can be a useful tool in determining changes in oxygenation of the 
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microvasculature, and when used in conjunction ektacytometry, can be used to confirm whether 
changes in erythrocyte deformability result in improved oxygenation of the tissue. 
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CHAPTER 3: METHODOLOGY 
 
The purpose of this study was to determine the effects of chronic omega-3 fatty acid 
supplementation on erythrocyte deformability and tissue oxygenation in highly trained cyclists 
during submaximal exercise in both normoxic and hypoxic conditions.  The aim was to establish 
a possible method for attenuating the potential limitations of reduced erythrocyte deformability 
during exercise in trained endurance athletes in both normoxic and hypoxic conditions. The 
primary dependent variables of interest in this study are elongation index (EI), via 
Ektacytometry; and muscle oxygen saturation, oxy-hemoglobin + myoglobin (oxy-Hb+Mb), and 
deoxy-hemoglobin + myoglobin concentrations (deoxy-Hb+Mb), from near infrared 
spectroscopy (NIRS).  
Subjects 
The experiments were performed on highly trained cyclists (n=13). Sample size was 
determined from a power analysis using published data [6]. Highly trained status is defined as a 
VO2 max ≥55ml/kg/min. Potential subjects who identify with any of the following were 
excluded from this study: 
1. A history of smoking in the last twelve months 
2. Omega-3 supplementation in the past 4 weeks, or fish consumption greater than 
one meal per week. 
3. Women who are post-menopausal, taking birth control medication or hormone 
replacement therapy, or pregnant or possibly pregnant 
4. A history of/current medical conditions such as pulmonary or cardiovascular 
disease. 
5. Known allergy to omega-3 or omega-6 PUFAs 
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Experimental Design 
 
Each subject will present for a total of five visits. 
 
Figure 9. Overview of subject visits 
 During the initial visit subjects completed an informed consent form.  
Immediately following, a graded maximal exercise test on an electronically braked cycle 
ergometer (Velotron, RacerMate Inc., Seattle, WA) was performed to determine both VO2 peak 
and peak power, to confirm whether the subject qualified as highly trained and establish the work 
rates for the subsequent visits, respectively. Subjects were informed of qualification at this point 
if the peak VO2 taken from a 30 second average of the data exceeds 55ml/kg/min. 
The subsequent two visits included three bouts submaximal cycling with the workloads 
of each bout set to 25, 50 and 75% of maximal power. The same protocol is to be followed for 
the second and third visits, with one performed in nomoxia, and the other in acute hypoxia (FIO2 
=15%; equivalent to 3000m / 9900ft altitude). During the hypoxic visit, the subject was exposed 
to the hypoxic gas starting 10 minutes prior to beginning exercise, and terminating upon 
completion of the final trial. Each of the submaximal cycling visits included the same exercise 
protocol, with each of the three bouts following this structure:  
 Resting Data  1 minute 
 Unloaded cycling  1 minute 
 Loaded cycling 3 minutes  
 Recovery Data 1 minute  
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During the final bout at 75% max power, after the initial 3 minutes of loaded cycling the subject 
continued until exhaustion, which was defined as an rpm below 60 or volitional exhaustion. A 
rest period of 5 minutes was given between each workload. 
After the third visit, the subjects then underwent the 6-weeks supplementation period. 
The subjects were instructed to maintain their training status upon enrolment for the duration of 
the study. Following the six weeks of either PUFA or placebo supplementation, the subjects 
returned for two more visits, following the same protocol as visit two and three.  
Treatment 
Following enrolment, the subjects were pair matched by age and baseline EI, and were 
blinded and randomized into placebo and supplementation groups. The PUFA group took gel 
capsules totaling 2g of DHA, 3g of EPA, and 100mg of Vitamin E daily for 6 weeks, while the 
placebo group was given iso-caloric doses of safflower oil capsules, an omega-6 PUFA shown 
not to affect erythrocyte deformability or endothelial function [24, 35]. The subjects were 
instructed to take half the daily dose in the morning, and half the daily dose in the evening every 
day for six weeks. A journal was provided for the subjects to track their intake, to ensure 
compliance. 
Measurements 
 
Near Infrared Spectroscopy 
NIRS (model 96208, ISS Inc., Champaign, IL) was used to determine oxygen saturation, 
oxy-hemoglobin+myoglobin, and deoxy-hemoglobin + myoglobin concentrations in the 
exercising muscle microcirculation by placing the detector on the vastus lateralis during the 
cycle protocol. A mark was made 15 cm proximal and5 cm lateral from the middle of the 
proximal border of the patella. The sensor was placed on that mark. The data of interest was 
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filtered, and an average was  taken of the last 30 seconds each stage of all three workloads (rest, 
unloaded, loaded and recovery data).  
 
Erythrocyte Deformability 
Ektacytometry (RheoScan-D300, Sewon Meditech, Inc., Seoul, Korea) was used to 
measure the Elongation Index (EI) via finger prick capillary samples. A 5 µL sample of blood 
was taken for each measurement. The sample is placed under a given shear stress, and EI can be 
determined by measuring the laser diffraction pattern during shear, and is measured as 
L − D
L + D
 
 where L is the length and D the width of the RBC under deformation[36]. For each of the four 
experimental visits, finger prick samples were taken before beginning the exercise and after the 
completion of the cycling trials. 
Metabolic Data 
For all trials, subjects were fitted with a face mask (#2700, Hans Rudolph Inc., Shawnee, 
KS) attached to a two-way non-rebreathing valve. Breath by breath values for ventilation and 
expired gas concentrations were measured by a Vmax Encore Metabolic Cart (CareFusion 
Corporation, San Diego, CA) to sample the metabolic data. Arterial oxygen saturation (SaO2) 
was monitored with fingertip pulse oximetry (Model PC-68A, Shenzen Creative Industry Co, 
Ltd., Shenzen, China). Heart rate was measured using a Polar heart rate monitor. 
Data Analysis 
A 2x2 split plot repeated measures ANOVA was done for each dependent variable of 
interest, with treatment (omega-3 or placebo) as the between groups factor, and time (pre- or 
post- supplementation) as the within groups factor. Tests of a priori sample main effects was also 
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done to determine differences in time within each treatment group, as well as differences in 
treatment groups for each time period. Statistical significance was set at an alpha of p<0.05. 
 
CHAPTER 4: RESULTS 
 
Subjects 
A total of seventeen subjects were enrolled in the study.   All of the subjects enrolled 
were able to surpass our inclusion criteria of a V̇O2 max of at least 55ml/kg/min, however, three 
subjects were unable to proceed past the initial V̇O2 max test, as we were unable to get an 
accurate reading from the NIRS.   One subject had to be removed from the final analysis, as their 
training during supplementation was not comparable to the 6 weeks prior to the initial testing. 
From their training logs we observed a 25% increase in training volume over the course of the 
study. Subjects included for final analysis (n=13) had a V̇O2 max of 64.0 ± 4.9 ml/kg/min and 
reached a maximal power of 300.0 ± 54.2 W.   Subject characteristics can be found in Table 1. 
Table 1 – Subject Characteristic Data  
 Omega-3 PUFA 
(n=6) 
Placebo 
(n=7) 
Grouped 
(n=13) 
    
    
Age 20±1.2 21.1±2.2 20.7±1.9 
Height 177.6±7.0 181.8±3.7 179.8±5.7 
Mass 78.9±6.7 77.6±5.9 78.21±6.3 
VO2max 60.2±4.1 67.3±2.6 64.0±4.9 
Max 
Power 
379±64 389±44 385±54 
    
 Table 1. Subject characteristics measures taken upon initial visit. 
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Erythrocyte deformability 
Data for erythrocyte deformability in the pre-supplementation hypoxic condition can be 
found in Table 2. When comparing baseline values to measurements taken post-exercise in the 
hypoxic condition prior to supplementation, there were no significant differences in Elongation 
Index (EI). Data for baseline erythrocyte deformability can be found in Table 3. After 
supplementation, there were no significant differences in baseline EI when compared to pre-
supplementation values. 
Table 2 – Hypoxic Erythrocyte Deformability Data  
 Omega-3 PUFA 
(n=6) 
Placebo 
(n=7) 
Grouped 
(n=13) 
 
Baseline  
Post-
Exercise Baseline  
Post-
Exercise Baseline  
Post-
Exercise 
Shear Stress       
       
5 Pa 0.320± 0.006 0.320±0.006 0.318±0.009 0.320±0.008 0.319±0.008 0.320±0.007 
10 Pa 0.384±0.009 0.382±0.006 0.383±0.014 0.387±0.012 0.383±0.012 0.385±0.010 
15 Pa 0.472±0.008 0.472±0.006 0.473±0.011 0.477±0.011 0.473±0.009 0.475±0.009 
20 Pa 0.571±0.006 0.574±0.004 0.576±0.011 0.576±0.004 0.574±0.009 0.575±0.004 
       
Erythrocyte deformability measures as measured via Ektacytometry (Elongation Index) at 5, 10, 15, and 20 Pa 
sheer stress. Baseline, baseline (resting) measures prior to 6-week supplementation period; Post-Exercise, 
measures following exercise protocol in Hypoxia (FiO2 = 15.0%), prior to 6-week supplementation period. 
Table 2. Pre-Supplementation deformability measures in hypoxic condition. 
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Table 3 – Baseline Erythrocyte Deformability Data  
 Omega-3 PUFA 
(n=6) 
Placebo 
(n=7) 
Grouped 
(n=13) 
 
Pre Post Pre Post Pre Post 
Shear Stress       
Normoxic Trial       
5 Pa 0.321±0.008 0.307±0.032 0.325±0.006 0.321±0.008 0.323±0.007 0.315±0.023 
10 Pa 0.386±0.010 0.380±0.018 0.390±0.009 0.386±0.011 0.388±0.010 0.383±0.015 
15 Pa 0.476±0.009 0.470±0.017 0.480±0.007 0.476±0.011 0.478±0.008 0.473±0.014 
20 Pa 0.575±0.002 0.564±0.190 0.577±0.005 0.575±0.009 0.576±0.004 0.570±0.016 
       
Hypoxic Trial       
5 Pa 0.320±0.006 0.322±0.004 0.318±0.009 0.321±0.006 0.319±0.008 0.321±0.006 
10 Pa 0.384±0.009 0.385±0.007 0.383±0.014 0.385±0.007 0.383±0.012 0.385±0.007 
15 Pa 0.472±0.008 0.475±0.006 0.473±0.011 0.476±0.006 0.473±0.009 0.476±0.006 
20 Pa 0.571±0.006 0.577±0.005 0.575±0.011 0.577±0.008 0.574±0.009 0.577±0.007 
Baseline erythrocyte deformability measures as measured via Ektacytometry (Elongation Index) at 5, 10, 15, and 20 Pa 
sheer stress. Pre, baseline (resting) measures prior to 6-week supplementation; Post, baseline measures following six 
weeks of supplementation of omega-3 PUFA, or safflower oil (placebo); PUFA, polyunsaturated fatty-acids. 
Table 3. Baseline deformability measures pre- and post-supplementation. 
Data for post- exercise erythrocyte deformability can be found in Table 4. We 
demonstrated a significant difference in elongation index (EI) measures taken at 20 Pascals in the 
hypoxic condition between Omega-3(0.580±0.002) and Placebo(0.574±0.006) groups in post-
exercise measures following the 6-week supplementation.  We also identified a significant 
increase in EI measures post-supplementation (0.580±0.002) compared to pre-supplementation 
(0.574±0.002) with the treatment group after exercise for the hypoxic condition. There was no 
significant difference between the pre- and post-supplementation values for the control group. 
We did not see a change in deformability at lower sheer stresses in the hypoxic condition, nor did 
we see any changes in in the normoxic condition. 
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Table 4 – Post- Exercise Erythrocyte Deformability Data  
 Omega-3 PUFA 
(n=6) 
Placebo 
(n=7) 
Grouped 
(n=13) 
 
Pre Post Pre Post Pre Post 
Shear Stress       
 Normoxic Trial       
5 Pa 0.321±0.007 0.321±0.006 0.322±0.008 0.322±0.003 0.321±0.007 0.322±0.005 
10 Pa 0.386±0.010 0.386±0.008 0.389±0.110 0.385±0.005 0.388±0.011 0.385±0.006 
15 Pa 0.476±0.009 0.475±0.009 0.478±0.009 0.476±0.005 0.477±0.009 0.475±0.007 
20 Pa 0.576±0.003 0.572±0.008 0.574±0.004 0.578±0.003 0.575±0.003 0.575±0.007 
       
 Hypoxic Trial       
5 Pa 0.320±0.006 0.323±0.006 0.320±0.008 0.320±0.009 0.320±0.007 0.322±0.008 
10 Pa 0.382±0.006 0.388±0.006 0.387±0.012 0.385±0.009 0.385±0.010 0.386±0.008 
15 Pa 0.472±0.006 0.480±0.005 0.477±0.011 0.475±0.007 0.475±0.009 0.477±0.007 
20 Pa 0.574±0.004 *#0.580±0.002 0.546±0.004 0.574±0.006 0.575±0.004 0.577±0.006 
Post- exercise erythrocyte deformability measures as measured via Ektacytometry (Elongation Index) at 5, 10, 15, and 20 Pa sheer 
stress. Pre, baseline (resting) measures prior to 6-week supplementation; Post, baseline measures following six weeks of 
supplementation of omega-3 PUFA, or safflower oil (placebo); PUFA, polyunsaturated fatty-acids. 
* significantly different from pre-supplementation (p > 0.05), #significantly different from placebo (p > 0.05), 
Table 4. Post-exercise deformability measures pre- and post-supplementation.
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NIRS 
In order to ensure we had an appropriate comparison given different baseline levels 
between subjects, for the NIRS data analysis we used the difference between the unloaded 
cycling prior to the first stage (25% of maximal power) and the end of exercise for each of the 
three stages, respectively. Figure 10 shows the NIRS data tracing during a typical exercise trial. 
The data collected during the normoxic trials can be found in table 5. 
NIRS Sample Tracing
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Figure 10. A sample tracing of the NIRS data collected during each of the exercise trials. 
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Table 5 – Near-Infrared Spectroscopy Data from Normoxic (FIO2 = 20.93%) Exercise Trials 
 Omega-3 PUFA 
(n=6) 
Placebo 
(n=7) 
Grouped 
(n=13) 
 
Pre Post Pre Post Pre Post 
Δ[OxyHb +Mb] (µM)       
      25% of Peak Power 0.88±1.56 1.38±1.67 0.07±1.34 0.53±5.21 0.45±1.50 0.92±4.01 
      50% of Peak Power -1.72 ±2.71 -2.53±1.90 -3.37 ±3.61 -0.53±5.18 -2.61±3.31 -1.51±4.13 
      75% of Peak Power -1.58±3.14 -3.65±1.98 -7.07±6.26 -2.94±5.25 -4.54±5.76 -3.27±4.09 
      Exhaustion -2.80±3.82 -4.22±5.40 -8.24±6.96 -5.83±5.37 -5.73±6.34 -5.08±5.44 
Δ [DeoxyHb +Mb] (µM)       
      25% of Peak Power 1.72±0.74 -0.57±7.60 3.60±1.17 4.66±3.14 2.73±1.37 2.25±6.23 
      50% of Peak Power 4.85±2.02 5.45±3.64 9.53±3.21 9.30±4.57 7.37±3.59 7.52±4.59 
      75% of Peak Power 7.75±3.82 9.32±5.16 14.50±6.69 12.86±6.78 11.38±6.49 11.22±6.34 
      Exhaustion 12.95±5.56 14.72±7.11 19.20±7.36 19.26±11.17 16.32±7.29 17.16±9.78 
Δ [Total Hb +Mb] (µM)       
      25% of Peak Power 2.67±1.99 4.25±1.71 3.66±1.53 5.19±3.26 3.20±1.83 4.75±2.70 
      50% of Peak Power 3.17±4.16 4.53±3.05 5.84±3.57 8.66±5.91 4.61±4.08 6.75±5.23 
      75% of Peak Power 6.20±5.58 5.62±3.79 7.41±3.07 9.91±8.16 6.85±4.45 7.93±6.86 
      Exhaustion 10.82±9.85 10.40±6.49 10.93±3.82 13.44±11.04 10.88±7.26 12.04±9.35 
Δ Tissue Saturation (%)       
      25% of Peak Power -1.32±0.53 -2.55±2.06 -2.90±1.12 -3.43±3.63 -2.17±1.20 -3.02±3.04 
      50% of Peak Power -5.60±0.83 -8.10±1.76 -8.51±2.65 -6.87±3.53 -7.17±2.49 -7.44±2.92 
      75% of Peak Power -8.13±2.13 -9.88±2.68 -13.67±7.45 -10.03±3.95 -11.11±6.90 -9.96±3.42 
      Exhaustion -13.95±1.04 -14.43±3.94 -17.03±7.83 -14.61±5.07 -15.61±5.99 -14.53±4.58 
The change in NIRS measures for each workload when compared to unloaded exercise prior to the first workload 
Pre, baseline testing prior to 6-week supplementation; Post, testing following six weeks of supplementation of omega-3 PUFA, or 
safflower oil (placebo); PUFA, polyunsaturated fatty-acids. 
Table 5. Near-Infrared Spectroscopy (NIRS) measures pre- and post-supplementation in Normoxic condition.
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Figure 11. Change in tissue saturation measures at four exercise intensities in Normoxia pre- and post-
supplementation 
 
Figure 11 displays the changes in Tissue Saturation (%) from unloaded exercise to 25%, 
50%, 75% of max power and at exhaustion (Max) in Normoxia in the Placebo group (left) and 
Omega-3 group (right).   All comparisons for tissue saturation measures showed no significant 
differences within groups. 
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Figure 12. Change in Oxy-Hemoglobin measures at four exercise intensities in Normoxia pre- and post-
supplementation 
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Figure 12 displays the changes in Oxy [Hb+Mb] from unloaded exercise to 25%, 50%, 
75% of max power and at exhaustion (Max) in Normoxia in the Placebo group (left) and Omega-
3 group (right).   There were no significant differences within groups between Pre- and Post-
Supplementation values at any common workload. 
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Figure 13. Change in Deoxy-Hemoglobin measures at four exercise intensities in Normoxia pre- and post-
supplementation 
 
Figure 13 displays the changes in Deoxy [Hb+Mb] from unloaded exercise to 25%, 50%, 
75% of max power and at exhaustion (Max) in Normoxia in the Placebo group (left) and Omega-
3 group (right).   There were no significant differences between Pre- and Post-Supplementation 
values at any common workload within groups. 
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Figure 14. Change in total hemoglobin measures at four exercise intensities in normoxia pre- and post-
supplementation 
 
Figure 14 displays the changes in Total [Hb+Mb] from unloaded exercise to 25%, 50%, 
75% of max power and at exhaustion (Max) in Normoxia in the Placebo group (left) and Omega-
3 group (right).   There were no significant differences between Pre- and Post-Supplementation 
values at any common workload within groups. 
 
Pre-Supplementation versus Post-Supplementation values in Hypoxia 
The data collected during the hypoxic trials can be found in table 6. Figure 15 displays 
the changes in tissue saturation (%) from Pre- to Post-Supplementation in Placebo (left) and 
Omega-3 (right) groups at each workload.   At each common workload, there were no significant 
differences between Pre- and Post-Supplementation values within groups. 
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Figure 15. Change in tissue saturation measures at four exercise intensities in hypoxia pre- and post-supplementation 
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Table 6 – Near-Infrared Spectroscopy Data from Hypoxic (FIO2 = 15.0%) Exercise Trials 
 Omega-3 PUFA 
(n=6) 
Placebo 
(n=7) 
Grouped 
(n=13) 
 
Pre Post Pre Post Pre Post 
Δ[OxyHb +Mb] (µM)       
      25% of Peak Power -2.03±1.30 -0.17±1.51 -1.03±2.10 -1.67±2.76 -1.49±1.84 -0.98±2.40 
      50% of Peak Power -4.55±2.53 -3.78±3.14 -5.79±2.75 -6.29±4.32 -5.22±2.72 -5.13±4.02 
      75% of Peak Power -4.52±3.28 -4.93±2.84 -7.13±4.96 -8.88 ±5.07 -5.92±4.47 -7.06±4.63 
Exhaustion -5.75 ±3.43 -5.03±2.97 -7.86 ±6.09 -9.04±6.17 -6.88±5.15 -7.19±5.35 
Δ [DeoxyHb +Mb] (µM)       
      25% of Peak Power 3.35±2.14 3.35±1.29 5.11±1.45 5.60±4.60 4.53±1.91 4.56±3.66 
      50% of Peak Power 8.28±3.84 7.38±3.50 10.77±4.46 12.45±7.23 9.62±4.37 10.12±6.34 
      75% of Peak Power 9.92±4.31 9.90±4.81 11.41±4.47 15.20±10.11 10.72±4.46 12.75±8.53 
Exhaustion 12.10±5.01 13.00±6.21 12.81±4.58 18.07±11.20 12.48±4.80 15.73±9.58 
Δ [Total Hb +Mb] (µM)       
      25% of Peak Power 1.82±2.12 3.20±1.98 4.04±2.05 3.91±2.58 3.01±2.36 3.58±2.35 
      50% of Peak Power 3.75±3.33 3.58±3.47 5.00±3.16 6.16±3.83 4.42±3.30 4.97±3.89 
      75% of Peak Power 5.42±5.30 5.00±4.83 4.27±5.22 6.31±7.71 4.80±5.29 5.71±6.57 
Exhaustion 6.37±5.98 7.93±7.23 4.96±4.68 9.03±8.71 5.61±5.37 8.52±8.08 
Δ Tissue Saturation (%)       
      25% of Peak Power -4.42±1.17 -3.48±0.90 -4.56±1.32 -4.41±3.53 -4.49±1.25 -3.98±2.70 
      50% of Peak Power -9.57±2.17 -8.60±2.17 -10.31±3.06 -11.04±4.86 -9.97±2.71 -9.92±4.04 
      75% of Peak Power -11.02±1.84 -11.17±1.91 -11.41±3.08 -14.23±7.64 -11.23±2.59 -12.82±5.96 
Exhaustion -13.40±1.52 -13.65±1.81 -12.60±3.54 -15.19±6.96 -12.98±2.83 -14.48±5.31 
The change in NIRS measures for each workload when compared to unloaded exercise prior to the first workload 
Pre, baseline testing prior to 6-week supplementation; Post, testing following six weeks of supplementation of omega-3 PUFA, or 
safflower oil (placebo); PUFA, polyunsaturated fatty-acids. 
Table 6. Near-Infrared Spectroscopy (NIRS) measures pre- and post-supplementation in hypoxic condition.
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Figure 16. Change in oxy-hemoglobin measures at four exercise intensities in hypoxia pre- and post-
supplementation. 
 
Figure 16 displays the changes in Oxy [Hb+Mb] from Pre- to Post-Supplementation in 
Placebo (left) and Omega-3 (right) groups at each workload.   At each common workload, there 
were no significant differences between Pre- and Post-Supplementation values within groups.  
Placebo - Hypoxia - Deoxy [Hb+Mb]
Workload (% of Power at VO
2
max)
25% 50% 75% Exh 25% 50% 75% Exh

D
e
o
x
y
 [
H
b
+
M
b
] 
fr
o
m
 U
n
lo
a
d
e
d
 E
x
e
rc
is
e
 (
u
M
)
0
5
10
15
20
25
30
Pre-Supplementation Post-Supplementation
Omega-3 - Hypoxia - Deoxy [Hb+Mb]
Workload (% of Power at VO
2
max)
25% 50% 75% Exh 25% 50% 75% Exh

D
e
o
x
y
 [
H
b
+
M
b
] 
fr
o
m
 U
n
lo
a
d
e
d
 E
x
e
rc
is
e
 (
u
M
)
0
5
10
15
20
25
30
Pre-Supplementation Post-Supplementation
 
Figure 17. Change in deoxy-hemoglobin measures at four exercise intensities in hypoxia pre- and post-
supplementation 
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Figure 17 displays the changes in Deoxy [Hb+Mb] from Pre- to Post-Supplementation in 
Placebo (left) and Omega-3 (right) groups at each workload.   At each common workload, there 
were no significant differences between Pre- and Post-Supplementation values within groups. 
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Figure 18. Change in total hemoglobin measures at four exercise intensities in hypoxia pre- and post-
supplementation 
 
Figure 18 displays the changes in Total [Hb+Mb] from Pre- to Post-Supplementation in 
Placebo (left) and Omega-3 (right) groups at each workload.   At each common workload, there 
were no significant differences between Pre- and Post-Supplementation values within groups. 
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CHAPTER 5: DISCUSSION 
The aim of this study was to determine the effects of chronic omega-3 poly-unsaturated 
fatty acid (PUFA) supplementation on erythrocyte deformability and tissue oxygenation in 
highly trained cyclists during submaximal exercise in both normoxic and hypoxic conditions.   
During exercise, as regional blood flow increases, blood perfuses into the microvasculature in 
order to supply meet the increased oxygen demand of the working muscles. The smallest of the 
capillaries can be as narrow as 3 m in diameter [1] and since erythrocytes are, on average, 7m 
in diameter, the tissues supplied by the microvasculature rely on the ability of erythrocytes to 
deform for the delivery of oxygen [2].   In cases where the erythrocytes are unable to adequately 
deform, they bypass the most narrow vessels of the microvasculature [3], thus causing areas of 
skeletal muscle to lack adequate oxygenation.   In order for maximal oxygen delivery to occur in 
the active skeletal muscle, erythrocyte deformability must be maintained to allow for passage 
through the microvasculature.  Our data indicate that there is neither a change in baseline 
erythrocyte deformability nor an attenuation of deformability decrease with exercise in hypoxia 
following PUFA supplementation, as indicated by Elongation Index measures. The data also 
failed to demonstrate any changes in microvascular tissue oxygenation via NIRS. This would 
suggest that omega-3 PUFA supplementation is likely not an advantage to mitigate endurance 
exercise performance impairment with acute exposure to altitude. 
A correlation has been demonstrated between erythrocyte deformability and phospholipid 
content in the cell membrane [12], and it has been demonstrated that chronic supplementation of 
PUFAs increases erythrocyte deformability and skeletal muscle blood flow [13].   However, 
whether any omega-3 mediated increase in erythrocyte deformability leads to improvements in 
microvascular oxygenation during exercise and/or hypoxic exposure has not been previously 
demonstrated.   By using ektacytometry to quantify erythrocyte deformability and NIRS to 
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evaluate tissue oxygenation during exercise, we intended to add novel information to the existing 
literature on omega-3 fatty acid supplementation and erythrocyte deformability.    
Erythrocyte Deformability 
Omega-3 supplementation has been shown to increase erythrocyte deformability by 
targeting the viscoelastic properties of the erythrocyte membrane. This is due to the 
incorporation of the polyunsaturated fatty acids into the cell membrane, which contributes to a 
more fluid cell membrane, allowing the cell to be more deformable [12]. Our findings did not 
support the hypothesis that deformability would decrease with exercise in hypoxia and increase 
with  PUFA supplementation, which conflicts with previous findings [13].  There are a few 
primary differences between our protocol and those who were able to demonstrate a change in 
deformability: measurement method, subject fitness levels, and exercise protocol.  
Despite having similar supplementation length and daily dosage of EPA, previous studies 
were able to demonstrate a significant difference in erythrocyte deformability following PUFA 
supplementation [13]. However, these studies employed a different measurement method to 
quantify erythrocyte deformability. First described by Reid et al, a filtration method [21] was 
commonly used to observe changes erythrocyte deformability prior to Ektacytometry becoming 
more prevalent in the literature. Where ektacytometry measures elongation index, the filtration 
method provides red cell filtration rate, or index of filtration, as an indicator of deformability. In 
using ektacytometry, we were unable to demonstrate a change in deformability with PUFA 
supplementation. However, recent research into deformability measurement methods has 
demonstrated not only do the two different measurement techniques not correlate with each 
other, and they suggest that erythrocyte deformability is a “property that is operationally defined 
by the measurement methodology” [37],  therefore despite using similar study designs, we still 
may not expect similar results due to varying measurement techniques.  
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For the  studies showing positive changes in deformability with PUFA supplementation 
[13], subjects were defined as healthy male subjects, whereas our subjects were highly trained 
cyclists (V̇O2max= 64.0 ±4.9 mL/kg/min). It has been suggested that erythrocyte deformability is 
higher in elite athletes than untrained controls [8]. Further research has attempted to demonstrate 
differences in erythrocyte deformability with varying types of sport[38], but the subjects did not 
perform a V̇O2max test, so it remains unclear whether there is a relationship between erythrocyte 
deformability and endurance levels. There is the possibility that due to their fitness levels, our 
subjects had already reached their maximal deformability levels, and were therefore not aided by 
the PUFA supplementation.   
One previous study with similarly trained subjects (V̇O2max= 58 ±6 mL/kg/min) was 
able to demonstrate a decrease in deformability with exercise at hypoxia, and an attenuation of 
this decrease in deformability with PUFA supplementation [6]. However, this study differed in 
methodology in a number of ways. They measured deformability via the filtration method and 
while using simulations of similar altitudes (3000m), they utilized a hypobaric chamber, where 
our methodology utilized normobaric hypoxia. The exercise protocol also varied, as they had 
their subjects cycle at an intensity equivalent to 70% of their V̇O2max for 1 hour, so it is possible 
that the prolonged exercise elicited a stronger response, which was able to demonstrate 
significant differences between supplementation and placebo groups. 
To our knowledge, there is only one study that has previously researched the changes in 
erythrocyte deformability with omega-3 supplementation in highly trained subjects with 
ektacytometry as their measurement method, however they were unable to demonstrate changes 
in erythrocyte deformability with PUFA supplementation in “well- trained” cyclists (V̇O2max= 
4.4 ± 0.1 L/min) [23].  Despite using the sample measurement technique, they varied in 
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supplementation composition and length, and utilized a prefixed absolute workload test set at 
70% of the subjects Wmax for their exercise protocol. 
Due to the variety of research protocol within the present body of literature, it is difficult 
to make comparisons between findings. From differing measurement techniques [6, 12, 13], 
subject fitness levels [12, 13], and exercise protocol [6, 23], it is evident that further research 
needs to be completed to determine the relationship between erythrocyte deformability and 
omega-3 supplementation in highly trained subjects.  
NIRS 
By measuring hemoglobin levels in the active skeletal muscles, NIRS can be a useful tool 
in determining changes in oxygenation of the microvasculature, and when used in conjunction 
ektacytometry, can be used to confirm whether changes in erythrocyte deformability result in 
improved oxygenation of the tissue. The research exploring the effect of erythrocyte 
deformability on microvascular oxygen delivery in highly trained individuals has not been 
extensively pursued and whether any omega-3 mediated increase in erythrocyte deformability 
leads to improvements in microvascular oxygenation during exercise and/or hypoxic exposure is 
currently unknown. 
Since we were unable to demonstrate a decrease in deformability with exercise in hypoxia, or 
a treatment effect of the omega-3 supplementation on baseline erythrocyte deformability, and 
only a marginal significant difference on post-exercise erythrocyte deformability measures, we 
would not expect to be able to demonstrate significant differences in microvascular tissue 
oxygenation.    
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Limitations 
Since there are many factors that influence erythrocyte deformability that can vary 
between individuals, an ideal methodology for this study would include a crossover design, with 
a washout period between supplementations and retest after the second supplementation period.   
Logistical concerns of subject recruitment and adherence over the longer time period were the 
cause of not selecting this design. The power analysis done prior to testing indicated 15 subjects 
would be necessary and the final subject number of this study was two short at 13, however 
based on the data collected it is unlikely that additional subjects would have altered the results. 
Since our subjects were all highly trained athletes, our results depending on their training 
remaining consistent between the six weeks prior to supplementation and the six week 
supplementation period. As demonstrated by the subject that was removed from the final 
analysis, finding a twelve week period where there are no changes in training levels for highly 
trained athletes can difficult to achieve. 
In order to keep record of the subjects’ supplementation adherence, they completed a 
supplementation log and were instructed to return the pills remaining at the end of the study. The 
levels of polyunsaturated fatty acids in their blood were not analyzed before and after 
supplementation, so their compliance cannot be confirmed, which could have altered our results. 
In comparing findings to previous research that has shown changes in erythrocyte 
deformability in highly trained individuals with PUFA supplementation, the lack of significance 
could be due to varying hypoxic exposure. A simulated altitude of 3000m in hypobaric hypoxia 
was used in previous research [6], and while we maintained a simulated altitude of 3000m, we 
did so with normobaric hypoxia with FIO2 =15%. Being that there is a potential for difference in 
results between normobaric and hypobaric hypoxia, a higher simulated altitude may have been 
necessary to see similar results. 
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Future Directions 
There are several novel aspects to this investigation, and therefore are many areas that 
merit further investigation. To our knowledge, we are the first to examine the changes of 
erythrocyte deformability with polyunsaturated fatty acid supplementation in highly trained 
individuals utilizing ektacytometry as a measurement methodology, alongside with confirming 
the effects on microvascular tissue oxygenation with near infrared spectroscopy (NIRS). Future 
research with these methodologies could add to the field of knowledge surrounding erythrocyte 
deformability and performance. 
 Since there is also limited knowledge on erythrocyte deformability in highly trained 
individuals and further research is necessary to confirm the deformability levels of highly trained 
athletes and determine whether there is room for improvement with omega-3 supplementation. 
Comparison between subjects with varied fitness levels could help bring insight into the effect of 
training status on erythrocyte deformability. This may result in finding that elite athletes may not 
benefit, but there may be room for a performance aid for recreational athletes as well a potential 
clinical application for exercise tolerance in untrained individuals. 
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SUPPLEMENTAL MATERIALS 
 
Appendix A: Subject Characteristic Data 
 
Subject Supplement Age Sex 
Height 
(cm) 
Mass 
(kg) 
VO2max 
(mL/kg/min) 
MaxPower 
(W) 
        1015 Omega-3 20 M 183.0 82.1 68.6 450 
1017 Omega-3 18 M 175.5 72.5 61.7 350 
1020 Omega-3 20 F 168.7 68.0 56.8 300 
1021 Placebo 19 M 184.8 84.2 67.9 450 
1022 Omega-3 21 M 177.4 84.2 57.4 325 
1024 Placebo 21 M 180.6 71.1 67.1 375 
1027 Placebo 21 M 178.7 72.2 69.6 375 
1029 Omega-3 21 M 171.2 79.3 56.9 375 
1033 Placebo 22 M 182.9 80.7 70.2 425 
1034 Omega-3 22 M 189.5 87.1 59.8 475 
1035 Placebo 19 M 186.8 86.9 67.6 400 
1036 Placebo 20 M 183.6 76.3 67.2 400 
1037 Placebo 26 M 175.1 72.1 61.4 300 
        Omega-3 Mean 20 
 
177.6 78.87 60.2 379 
 
SD 1 
 
7.7 7.29 4.5 70 
Placebo Mean 21 
 
181.8 77.64 67.3 389 
 
SD 2 
 
4.0 6.36 2.9 48 
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Appendix B: Erythrocyte Deformability Data 
 
Subject Supplement BLPreN5Pa BLPostN5Pa BLPreH5Pa BLPostH5Pa BikePreN5Pa BikePostN5Pa BikePreH5Pa BikePostH5Pa 
          1015 Omega-3 0.32033 0.324096 0.318463 0.318391 0.31353 0.321152 0.317627 0.32604 
1017 Omega-3 0.310285 0.326433 0.315324 0.322035 0.313772 0.323711 0.322725 0.319975 
1020 Omega-3 0.312107 0.329273 0.310985 0.324136 0.324713 0.327552 0.319583 0.327389 
1021 Placebo 0.312229 0.318978 0.316848 0.316881 0.31279 0.322135 0.311651 0.299661 
1022 Omega-3 0.326613 0.297534 0.318542 0.328869 0.318976 0.328795 0.308138 0.325348 
1024 Placebo 0.332223 0.304511 0.318199 0.322163 0.318837 0.319554 0.319188 0.323978 
1027 Placebo 0.322827 0.320403 0.300759 0.324286 0.316412 0.326754 0.309431 0.324098 
1029 Omega-3 0.326953 0.240995 0.328522 0.314835 0.324722 0.311072 0.326974 0.327975 
1033 Placebo 0.324320 0.330341 0.335229 0.325003 0.328549 0.318887 0.329256 0.328982 
1034 Omega-3 0.330168 0.325654 0.328050 0.321189 0.33178 0.316018 0.322549 0.310807 
1035 Placebo 0.326937 0.326869 0.316672 0.307477 0.329801 0.321489 0.315236 0.324724 
1036 Placebo 0.328935 0.328511 0.315421 0.322400 0.332460 0.326468 0.325801 0.317048 
1037 Placebo 0.324542 0.320021 0.321463 0.328993 0.313084 0.316754 0.332003 0.323619 
          Omega-3 Mean 0.321076 0.307331 0.319981 0.321576 0.321249 0.321383 0.319599 0.322922 
 
SD 0.008310 0.034524 0.007001 0.004810 0.007150 0.006835 0.006451 0.006581 
Placebo Mean 0.324573 0.321376 0.317799 0.321029 0.321705 0.321720 0.320367 0.320301 
 
SD 0.006306 0.008703 0.010129 0.006998 0.008348 0.003775 0.008824 0.009751 
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Subject Supplement BLPreN10Pa BLPostN10Pa BLPreH10Pa BLPostH10Pa BikePreN10Pa BikePostN10Pa BikePreH10Pa BikePostH10Pa 
          1015 Omega-3 0.382316 0.386384 0.378467 0.380696 0.376125 0.383497 0.378366 0.389694 
1017 Omega-3 0.374507 0.390634 0.376989 0.382908 0.376912 0.384793 0.384265 0.382266 
1020 Omega-3 0.374365 0.398562 0.372994 0.387147 0.388844 0.395032 0.379715 0.394154 
1021 Placebo 0.374001 0.381040 0.381296 0.378265 0.376216 0.383083 0.377816 0.367856 
1022 Omega-3 0.391066 0.365668 0.381311 0.399992 0.380890 0.397577 0.374910 0.389450 
1024 Placebo 0.406460 0.368480 0.381516 0.384901 0.382785 0.381550 0.383952 0.387772 
1027 Placebo 0.386377 0.380519 0.367342 0.386243 0.380137 0.392247 0.372692 0.385940 
1029 Omega-3 0.390866 0.347439 0.396642 0.376336 0.388041 0.375818 0.393451 0.395046 
1033 Placebo 0.385958 0.402997 0.414189 0.388701 0.395129 0.380696 0.399450 0.398686 
1034 Omega-3 0.402133 0.390671 0.395245 0.383539 0.406630 0.378870 0.381925 0.378233 
1035 Placebo 0.392130 0.391136 0.377275 0.374813 0.399795 0.382986 0.376452 0.386988 
1036 Placebo 0.397592 0.396912 0.375880 0.385040 0.407786 0.392365 0.389231 0.379601 
1037 Placebo 0.388425 0.382144 0.385428 0.398196 0.379402 0.381189 0.407677 0.386935 
          Omega-3 Mean 0.385876 0.379893 0.383608 0.385103 0.386240 0.385931 0.382105 0.388141 
 
SD 0.010868 0.019379 0.009935 0.008117 0.011347 0.008693 0.006401 0.006643 
Placebo Mean 0.390135 0.386175 0.383275 0.385166 0.388750 0.384874 0.386753 0.384825 
 
SD 0.010173 0.011623 0.014787 0.007509 0.012106 0.005153 0.012889 0.009367 
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Subject Supplement BLPreN15Pa BLPostN15Pa BLPreH15Pa BLPostH15Pa BikePreN15Pa BikePostN15Pa BikePreH15Pa BikePostH15Pa 
          1015 Omega-3 0.472282 0.476422 0.468041 0.470558 0.466412 0.474969 0.468255 0.481433 
1017 Omega-3 0.466294 0.480595 0.466705 0.473329 0.467335 0.470330 0.474484 0.474185 
1020 Omega-3 0.464102 0.484298 0.462106 0.477660 0.479560 0.485490 0.468997 0.484505 
1021 Placebo 0.465405 0.472553 0.474006 0.467906 0.465869 0.472152 0.471555 0.460139 
1022 Omega-3 0.480131 0.460206 0.472692 0.485416 0.471613 0.486225 0.467974 0.479114 
1024 Placebo 0.489995 0.454688 0.474559 0.478570 0.474601 0.473932 0.474574 0.479777 
1027 Placebo 0.477764 0.471521 0.459003 0.477253 0.470855 0.483356 0.463431 0.475158 
1029 Omega-3 0.480383 0.436470 0.484867 0.467726 0.477949 0.466797 0.484152 0.486104 
1033 Placebo 0.476697 0.489304 0.493695 0.480733 0.483114 0.472142 0.487482 0.485909 
1034 Omega-3 0.490664 0.483004 0.478667 0.476673 0.493521 0.464191 0.470012 0.472056 
1035 Placebo 0.480062 0.480825 0.467532 0.466276 0.486924 0.473150 0.465294 0.474284 
1036 Placebo 0.486772 0.488903 0.464243 0.478094 0.492806 0.482267 0.478970 0.471477 
1037 Placebo 0.480580 0.473126 0.481029 0.484639 0.472291 0.472765 0.495895 0.476007 
          Omega-3 Mean 0.475643 0.470166 0.472180 0.475227 0.476065 0.474667 0.472312 0.479566 
 
SD 0.010001 0.018693 0.008389 0.006221 0.010096 0.009395 0.006268 0.005589 
Placebo Mean 0.479611 0.475846 0.473438 0.476210 0.478066 0.475681 0.476743 0.474679 
 
SD 0.007895 0.011979 0.011528 0.006700 0.009724 0.004920 0.011740 0.007915 
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Subject Supplement BLPreN20Pa BLPostN20Pa BLPreH20Pa BLPostH20Pa BikePreN20Pa BikePostN20Pa BikePreH20Pa BikePostH20Pa 
          1015 Omega-3 0.575022 0.576832 0.573359 0.573964 0.572481 0.579877 0.574090 0.583061 
1017 Omega-3 0.574637 0.577653 0.571775 0.577343 0.572143 0.563409 0.576544 0.581391 
1020 Omega-3 0.570315 0.568706 0.567947 0.578356 0.579018 0.580576 0.573281 0.579711 
1021 Placebo 0.577168 0.580030 0.581317 0.572731 0.567670 0.573211 0.580435 0.564118 
1022 Omega-3 0.574499 0.531696 0.578157 0.568235 0.577453 0.576324 0.571799 0.576338 
1024 Placebo 0.567677 0.554158 0.584939 0.587779 0.579935 0.582784 0.576289 0.582695 
1027 Placebo 0.580181 0.578644 0.564392 0.579622 0.575098 0.581142 0.572672 0.573999 
1029 Omega-3 0.576596 0.544415 0.574730 0.577922 0.576486 0.571550 0.580850 0.582350 
1033 Placebo 0.578397 0.572533 0.562994 0.582952 0.573550 0.579498 0.575403 0.572605 
1034 Omega-3 0.577982 0.584447 0.560642 0.585216 0.576413 0.559396 0.569676 0.577951 
1035 Placebo 0.572057 0.576967 0.575412 0.562719 0.573372 0.576405 0.569373 0.568701 
1036 Placebo 0.577747 0.585133 0.568660 0.585311 0.572201 0.577419 0.576500 0.579268 
1037 Placebo 0.582885 0.577878 0.593516 0.570413 0.578146 0.576292 0.580344 0.573265 
          Omega-3 Mean 0.574842 0.563958 0.571102 0.576839 0.575666 0.571855 0.574373 0.580134 
 
SD 0.002593 0.021064 0.006129 0.005589 0.002765 0.008798 0.003915 0.002623 
Placebo Mean 0.576587 0.575049 0.575890 0.577361 0.574282 0.578107 0.575859 0.573522 
 
SD 0.005123 0.009949 0.011351 0.009057 0.004020 0.003257 0.003960 0.006191 
BL – Baseline    Pre – Pre-supplementation   H – Hypoxia 
B – Bike (post- exercise)   Post – Post-supplementation  N – Normoxia 
5/10/15/20Pa – Pascals of Sheer Stress 
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Appendix C: NIRS Data 
 
Subject Group DN025S DN025O DN025D DN025T DN050S DN050O DN050D DN050T 
          
1015 Omega-3 -1.10 3.90 3.00 6.90 -4.50 3.90 7.60 11.40 
1017 Omega-3 -0.40 0.80 0.50 1.30 -5.70 -3.80 2.50 -1.30 
1020 Omega-3 -1.70 1.00 1.50 2.50 -4.60 -0.90 2.70 1.80 
1021 Placebo -2.00 -0.20 2.50 2.40 -6.00 -4.50 5.80 1.40 
1022 Omega-3 -2.10 -1.40 2.10 0.80 -5.70 -4.00 3.50 -0.50 
1024 Placebo -2.40 0.10 3.40 3.40 -13.30 -10.50 14.70 4.10 
1027 Placebo -4.20 -1.30 5.30 4.00 -7.70 -3.00 9.80 6.70 
1029 Omega-3 -1.40 0.40 1.60 2.20 -6.80 -2.80 6.70 4.10 
1033 Placebo -2.30 0.20 2.60 2.60 -10.40 -4.80 9.50 4.60 
1034 Omega-3 -1.20 0.60 1.60 2.30 -6.30 -2.70 6.10 3.50 
1035 Placebo -2.60 2.40 4.80 7.20 -8.40 0.80 12.80 13.60 
1036 Placebo -5.00 -1.90 4.50 2.70 -9.20 -2.60 9.10 6.50 
1037 Placebo -1.80 1.20 2.10 3.30 -4.60 1.00 5.00 4.00 
          
Omega-3 Mean         
 SD -1.32 0.88 1.72 2.67 -5.60 -1.72 4.85 3.17 
Placebo Mean 0.58 1.71 0.82 2.18 0.91 2.96 2.21 4.56 
 SD -2.90 0.07 3.60 3.66 -8.51 -3.37 9.53 5.84 
 
Subject Group DN075S DN075O DN075D DN075T DN0maxS DN0maxO DN0maxD DN0maxT 
          1015 Omega-3 -6.90 4.90 11.50 16.40 -13.50 3.20 17.70 24.80 
1017 Omega-3 -8.40 -3.30 4.50 1.20 -14.90 -7.30 7.40 0.00 
1020 Omega-3 -5.00 -0.40 3.20 2.80 -13.90 -3.40 8.50 5.10 
1021 Placebo -6.40 -3.90 6.70 2.90 -13.10 -2.50 18.00 15.60 
1022 Omega-3 -7.30 -4.20 4.50 0.30 -12.00 -5.80 7.20 1.40 
1024 Placebo -18.40 -13.90 21.40 7.30 -20.70 -14.20 25.90 11.50 
1027 Placebo -11.40 -4.00 15.20 11.20 -16.00 -8.70 20.10 11.40 
1029 Omega-3 -11.80 -3.60 13.00 9.50 -15.20 1.40 21.50 23.00 
1033 Placebo -28.90 -18.30 25.90 7.50 -33.70 -20.90 31.80 10.80 
1034 Omega-3 -9.40 -2.90 9.80 7.00 -14.20 -4.90 15.40 10.60 
1035 Placebo -9.50 -1.10 13.30 12.20 -12.30 -2.00 17.60 15.60 
1036 Placebo -14.90 -8.00 12.90 5.00 -16.30 -9.50 13.60 4.20 
1037 Placebo -6.10 -0.30 6.10 5.80 -7.10 0.10 7.40 7.40 
          Omega-3 Mean 
        
 
SD -8.13 -1.58 7.75 6.20 -13.95 -2.80 12.95 10.82 
Placebo Mean 2.33 3.44 4.19 6.11 1.14 4.19 6.09 10.79 
 
SD -13.66 -7.07 14.50 7.41 -17.03 -8.24 19.20 10.93 
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Subject Group DN125S DN125O DN125D DN125T DN150S DN150O DN150D DN150T 
          
1015 Omega-3 -2.50 2.10 -17.30 5.70 -10.30 -5.90 9.70 3.70 
1017 Omega-3 -2.40 0.30 1.70 2.00 -6.90 -2.20 3.80 1.60 
1020 Omega-3 0.00 3.00 1.10 3.90 -6.40 -1.10 4.00 2.70 
1021 Placebo -0.40 3.20 1.70 4.80 -1.00 2.70 2.30 4.90 
1022 Omega-3 -6.20 -1.50 3.60 2.10 -10.70 -4.00 5.90 1.90 
1024 Placebo -3.60 -2.20 4.10 1.90 -9.20 -6.40 10.40 4.00 
1027 Placebo -11.10 -9.50 11.40 1.90 -12.80 -8.80 14.80 6.00 
1029 Omega-3 -3.70 1.00 5.20 6.20 -7.80 -1.80 -0.60 7.60 
1033 Placebo 0.90 8.50 2.50 11.00 -7.00 5.60 15.00 20.50 
1034 Omega-3 -0.50 3.40 2.30 5.60 -6.50 -0.20 9.90 9.70 
1035 Placebo -2.40 3.70 4.90 8.60 -6.00 4.50 10.20 14.80 
1036 Placebo -5.20 -0.60 6.10 5.60 -8.30 -3.40 8.80 5.40 
1037 Placebo -2.20 0.60 1.90 2.50 -3.80 1.40 3.60 5.00 
          
Omega-3 Mean -2.55 1.38 -0.57 4.25 -8.10 -2.53 5.45 4.53 
 SD 2.25 1.83 8.33 1.87 1.93 2.08 3.99 3.34 
Placebo Mean -3.43 0.53 4.66 5.19 -6.87 -0.63 9.30 8.66 
 SD 3.93 5.63 3.39 3.53 3.81 5.60 4.94 6.39 
 
Subject Group DN175S DN175O DN175D DN175T DN1maxS DN1maxO DN1maxD DN1maxT 
          1015 Omega-3 -11.20 -5.30 11.20 5.80 -17.20 -9.30 17.30 7.90 
1017 Omega-3 -5.80 -1.30 3.50 2.20 -8.40 -0.80 5.70 4.80 
1020 Omega-3 -7.20 -1.80 4.40 2.40 -11.00 2.30 9.70 11.70 
1021 Placebo -2.70 0.90 3.60 4.50 -8.20 -3.90 8.20 4.30 
1022 Omega-3 -11.60 -4.30 6.40 2.10 -17.50 -7.40 9.30 1.90 
1024 Placebo -12.00 -10.00 12.70 2.70 -19.40 -14.10 22.80 8.70 
1027 Placebo -15.80 -10.80 18.60 7.80 -17.00 -12.00 20.00 8.00 
1029 Omega-3 -9.80 -2.40 12.00 9.60 -13.00 1.40 20.10 21.50 
1033 Placebo -12.80 2.50 24.90 27.50 -22.40 -4.80 43.10 38.40 
1034 Omega-3 -13.70 -6.80 18.40 11.60 -19.50 -11.50 26.20 14.60 
1035 Placebo -9.40 2.10 13.60 15.70 -14.10 -0.50 19.40 18.90 
1036 Placebo -10.60 -5.00 11.10 6.10 -13.50 -7.40 13.90 6.50 
1037 Placebo -6.90 -0.30 5.50 5.10 -7.70 1.90 7.40 9.30 
          Omega-3 Mean -9.88 -3.65 9.32 5.62 -14.43 -4.22 14.72 10.40 
 
SD 2.94 2.17 5.65 4.15 4.31 5.91 7.79 7.10 
Placebo Mean -10.03 -2.94 12.86 9.91 -14.61 -5.83 19.26 13.44 
 
SD 4.26 5.67 7.32 8.82 5.47 5.80 12.06 11.93 
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Subject Group DH025S DH025O DH025D DH025T DH050S DH050O DH050D DH050T 
          1015 Omega-3 -4.50 -3.20 3.60 0.50 -8.90 -4.20 8.40 4.30 
1017 Omega-3 -3.60 -3.10 1.90 -1.30 -10.80 -6.30 6.60 0.30 
1020 Omega-3 -3.10 -0.40 2.30 1.80 -6.00 -2.30 3.70 1.40 
1021 Placebo -3.60 -0.20 3.40 3.10 -5.40 -2.10 4.20 2.10 
1022 Omega-3 -3.80 -1.20 2.00 0.90 -8.90 -3.50 4.60 1.20 
1024 Placebo -2.40 3.50 5.00 8.30 -11.50 -5.20 15.40 10.10 
1027 Placebo -6.60 -3.20 7.70 4.50 -13.40 -8.80 14.70 5.90 
1029 Omega-3 -4.80 -0.70 5.60 4.90 -9.60 -1.80 12.00 10.10 
1033 Placebo -4.60 -2.00 6.10 4.10 -12.20 -7.90 15.90 8.10 
1034 Omega-3 -6.70 -3.60 7.70 4.10 -13.20 -9.20 14.40 5.20 
1035 Placebo -4.70 -3.00 4.50 1.50 -9.30 -7.70 7.80 0.10 
1036 Placebo -6.00 -1.20 5.80 4.60 -13.80 -7.40 11.50 4.20 
1037 Placebo -4.00 -1.10 3.30 2.20 -6.60 -1.40 5.90 4.50 
          Omega-3 Mean -4.42 -2.03 3.85 1.82 -9.57 -4.55 8.28 3.75 
 
SD 1.28 1.42 2.35 2.32 2.38 2.78 4.21 3.65 
Placebo Mean -4.56 -1.03 5.11 4.04 -10.31 -5.79 10.77 5.00 
 
SD 1.42 2.26 1.57 2.21 3.31 2.97 4.82 3.41 
 
Subject Group DH075S DH075O DH075D DH075T DH0maxS DH0maxO DH0maxD DH0maxT 
          1015 Omega-3 -9.80 -0.30 12.00 11.70 -13.00 -1.50 15.90 14.40 
1017 Omega-3 -10.70 -7.00 6.20 -0.80 -12.50 -8.10 7.20 -0.90 
1020 Omega-3 -9.20 -4.80 5.10 0.20 -12.70 -6.10 7.20 1.10 
1021 Placebo -7.30 -3.30 5.50 2.10 -8.20 -2.70 6.80 4.10 
1022 Omega-3 -11.80 -4.50 6.30 2.00 -12.90 -4.50 7.10 2.70 
1024 Placebo -15.20 -9.40 19.30 9.70 -17.30 -12.00 21.30 9.20 
1027 Placebo -13.20 -7.60 15.40 7.90 -15.00 -10.70 16.00 5.30 
1029 Omega-3 -9.90 -0.80 13.20 12.40 -12.60 -2.60 16.40 13.80 
1033 Placebo -11.90 -16.00 9.00 -7.00 -15.80 -18.80 13.50 -5.30 
1034 Omega-3 -14.70 -9.70 16.70 7.00 -16.80 -11.70 18.80 7.10 
1035 Placebo -12.40 -8.10 12.20 4.20 -11.00 -4.30 13.10 8.80 
1036 Placebo -13.60 -6.90 11.60 4.70 -13.50 -7.30 11.20 3.90 
1037 Placebo -6.30 1.40 6.90 8.30 -7.40 0.80 7.80 8.70 
          Omega-3 Mean -11.02 -4.52 9.92 5.42 -13.42 -5.75 12.10 6.37 
 
SD 2.02 3.60 4.72 5.80 1.67 3.76 5.49 6.55 
Placebo Mean -11.41 -7.13 11.41 4.27 -12.60 -7.86 12.81 4.96 
 
SD 3.33 5.36 4.83 5.64 3.83 6.58 4.94 5.07 
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Subject Group DH125S DH125O DH125D DH125T DH150S DH150O DH150D DH150T 
          1015 Omega-3 -4.50 -0.40 5.70 5.20 -9.50 -4.80 10.70 5.80 
1017 Omega-3 -4.00 -1.40 2.20 0.80 -7.10 -3.30 3.80 0.50 
1020 Omega-3 -3.50 -0.20 2.10 2.00 -10.00 -5.40 4.00 -1.40 
1021 Placebo -2.00 1.20 2.40 3.60 -5.10 -1.50 4.00 2.50 
1022 Omega-3 -3.70 -0.10 2.40 2.30 -7.40 -1.30 4.60 3.40 
1024 Placebo -6.50 -3.20 7.40 4.10 -12.80 -9.40 13.70 4.30 
1027 Placebo -11.10 -7.60 14.40 6.80 -20.90 -14.70 25.60 10.90 
1029 Omega-3 -1.60 2.90 3.50 6.50 -5.50 1.00 8.40 9.30 
1033 Placebo -5.40 -1.10 8.20 7.20 -13.40 -7.80 19.50 11.60 
1034 Omega-3 -3.60 -1.80 4.20 2.40 -12.10 -8.90 12.80 3.90 
1035 Placebo -4.60 -1.30 5.00 3.60 -9.60 -2.50 11.20 8.70 
1036 Placebo -1.90 0.80 2.60 3.40 -7.50 -3.60 7.00 3.40 
1037 Placebo 0.60 -0.50 -0.80 -1.30 -8.00 -4.50 6.20 1.70 
          Omega-3 Mean -3.48 -0.17 3.35 3.20 -8.60 -3.78 7.38 3.58 
 
SD 0.99 1.65 1.42 2.17 2.38 3.44 3.83 3.80 
Placebo Mean -4.41 -1.67 5.60 3.91 -11.04 -6.29 12.46 6.16 
 
SD 3.82 2.99 4.97 2.79 5.24 4.66 7.81 4.14 
 
Subject Group DH175S DH175O DH175D DH175T DH1maxS DH1maxO DH1maxD DH1maxT 
          1015 Omega-3 -10.50 -3.10 13.20 10.00 -13.80 -4.30 18.00 13.60 
1017 Omega-3 -9.80 -5.00 5.10 0.10 -11.50 -5.80 6.00 0.10 
1020 Omega-3 -10.50 -5.80 4.10 -1.60 -15.90 -6.30 7.60 1.30 
1021 Placebo -5.80 -2.60 4.20 1.60 -3.70 0.00 3.40 3.40 
1022 Omega-3 -11.20 -3.20 6.70 3.60 -11.60 -3.30 7.00 3.70 
1024 Placebo -15.10 -7.30 18.90 11.60 -19.90 -10.20 25.70 15.40 
1027 Placebo -30.30 -18.40 31.60 13.20 -25.70 -18.10 32.50 14.50 
1029 Omega-3 -9.70 -1.90 13.40 11.60 -13.10 -0.40 20.80 20.50 
1033 Placebo -17.70 -12.40 25.20 12.70 -20.60 -14.30 30.50 16.20 
1034 Omega-3 -15.30 -10.60 16.90 6.30 -16.00 -10.10 18.60 8.40 
1035 Placebo -12.70 -3.70 15.10 11.40 -12.90 -0.70 18.10 17.40 
1036 Placebo -11.20 -6.90 9.70 2.90 -14.60 -8.80 12.90 4.10 
1037 Placebo -6.80 -10.90 1.70 -9.20 -8.90 -11.20 3.40 -7.80 
          Omega-3 Mean -11.17 -4.93 9.90 5.00 -13.65 -5.03 13.00 7.93 
 
SD 2.10 3.11 5.27 5.29 1.99 3.25 6.80 7.92 
Placebo Mean -14.23 -8.89 15.20 6.31 -15.19 -9.04 18.07 9.03 
 
SD 8.25 5.47 10.93 8.33 7.52 6.67 12.10 9.41 
 
 
 
 
D – Delta from 25% Unloaded   25 – Trial at 25% of Max Power   S – Tissue Saturation (%) 
N – Normoxia    50 – Trial at 25% of Max Power   O – [OxyHB] (µm) 
H – Hypoxia    75 – Trial at 25% of Max Power   D – [DeoxyHB] (µm) 
0 – Pre-supplementation  Max – at Exhaustion    T – Total [HB+MB] (µm) 
1 – Post-supplementation  
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Appendix D: Informed Consent Form 
 
INDIANA UNIVERSITY INFORMED CONSENT STATEMENT FOR 
 
The effects of altered erythrocyte deformability on microvasculature oxygenation and exercise tolerance in adults with type 2 
diabetes 
 
You are invited to participate in a research study that will help determine the effects of omega-3 fatty acid (fish oil) 
supplementation on how you complete an exercise task.  You were selected as a possible subject because you identified 
that you were either:  a) a type 2 diabetic,  b) an individual who does not regularly engage in training / physical activity, or 
c) a highly endurance trained individual.  We ask that you read this form and ask any questions you may have before 
agreeing to be in the study.  
 
Disclaimer:  It is possible that you will not qualify for the study following the completion of the blood test, height, weight, 
or maximal exercise test. 
 
The study is being conducted by Robert F. Chapman, Ph.D. (Principal Investigator), Timothy Mickleborough, PhD, Chad 
Wiggins, and Josh Foss in the Department of Kinesiology at Indiana University-Bloomington, and Kieren Mather, MD of 
the Department of Medicine at Indiana University.  This study is funded by a 2013 American Diabetes Association 
Innovation Award. 
 
 
STUDY PURPOSE 
 
The purpose of the proposed study is to investigate how six weeks of omega-3 fatty acid (fish oil) supplements affects 
your ability to complete various exercise tasks.   
 
 
NUMBER OF PEOPLE TAKING PART IN THE STUDY: 
 
If you agree to participate, you will be one of 60 subjects who will be participating in this research. 
 
 
PROCEDURES FOR THE STUDY: 
 
If you agree to be in the study, the following items are included: 
 
An invitation will be extended to visit the Human Performance laboratory a total of 6 times over a time period of 
approximately 10-12 weeks.  Each visit will be done at a previously agreed-upon time.  The first two visits last about 60 
minutes and the remaining four visits last about 75 minutes.  You should refrain from drinking caffeine for at least 8 hours 
prior to your visit.  If you are an endurance trained athlete, you should refrain from exhaustive exercise (exercise that 
causes significant fatigue) for 24 hours prior to each visit.  If you are an untrained individual (completing less than 90 
minutes of physical activity a week), we ask that you maintain the same low level of physical activity throughout the 
study. 
 
Visit #1 
This visit includes a blood draw to measure your blood cholesterol, blood glucose, and hemoglobin values.   
 
Visit #2 
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This visit includes the following tests: a) measures of your height, weight, resting pulse, and resting blood pressure, and b) 
a maximal exercise test on a stationary bicycle.   
 
Visits #3 through #6 
These visits include the following tests:  a) a forearm handgrip test (i.e. repeated squeezing against a resistance), and b) a 
submaximal exercise test on a stationary bicycle.  For these tests, you will either breathe room air or low oxygen air, 
simulating an altitude of approximately 9,900 feet, which is equivalent to an altitude you might experience in the Rocky 
Mountains. 
 
Between Visits #4 and #5, you will be asked to take capsules that are omega-3 (fish oil) supplements or placebos 
(capsules of safflower oil that look like the fish oil supplement).  You will take 8 capsules a day, 4 in the morning and 4 in 
the evening, each day for 6 weeks (42 consecutive days).  You will be asked to record the date and time you take your 
capsules on a supplement diary sheet, which we will provide you.  You may also record any comments you may have on 
this sheet.  You will be asked to return the supplement diary sheet, the supplement containers, and any unused pills with 
your final visit to the lab (Visit #6). 
 
 
Each of the tests and supplement routine is described below. 
 
Blood draw (visit #1 only).   A small amount of blood will be collected to measure your cholesterol, glucose, and 
hemoglobin levels.  For this test, the inside of your arm, opposite your elbow will be swabbed with alcohol and a sterile 
needle will be briefly inserted.  A small amount of blood (about 4 teaspoons) will be collected into a tube for analysis. 
 
Height, weight, heart electrical activity, and blood pressure measures.  Height will be measured by asking you to 
stand against a wall and a device will be lowered until it touches the top of your head.  Weight will be measured by having 
you sit on a chair, which is placed on a scale.  Blood pressure will be measured by placing a cuff around your upper arm.  
The cuff will be inflated, squeezing your upper arm, and quickly deflated.  Adhesive electrodes will be placed on your 
chest and wires attached to monitor the electrical activity of your heart.   
 
Maximal Cycle Exercise Test (visit #2 only).  This exercise test will be completed on a stationary bicycle.  Resting 
measurements will be collected for 5 minutes and followed by a 5 minute warm-up at a pace you select.  The test begins 
with cycling at between 70 - 100 rpm with a light resistance load.  Every minute, a small amount of additional resistance 
will be added until you can no longer maintain the required power output.  The goal is for you to exercise for as long as 
you can, and for most individuals, this is about 8-12 minutes of pedaling.   
 
Forearm Handgrip Test (visits #3 through #6 only).  For this test, you will be asked to lie down on a padded table with 
your dominant arm (the arm you use to throw a ball) held out away from your side, resting on a table.  You will be asked 
to wrap your fingers around a handgrip device, which is similar to a handle on a suitcase.  You will be asked to squeeze 
the handle as hard as you can 3 times, resting between each squeeze.  You will then be asked to perform 3 different 
exercise bouts of repeated squeezing.  Repeated squeezing will be 5 seconds of squeezing and 5 seconds of relaxing.  An 
audio recording will tell you when to squeeze and when to relax.  The first two exercise bouts of repeated squeezing will 
be for 3 minutes, separated by 5 minutes of rest.  The first bout will be at a low effort (17% of your maximal squeeze 
force) and the second at a medium effort (33% of maximal squeeze force).  The third and last bout of repeated squeezing 
will be at 50% of your maximal squeeze force, done for as long as you can, or until your force falls to less than 33% of 
your maximal squeeze force for 3 consecutive squeezes.  Normally, this third bout of repeated squeezing lasts about 4 to 7 
minutes. You will be able to view a monitor that tells how hard you are squeezing and what target you are trying to 
achieve. 
 
Submaximal Cycle Exercise Test (visits #3 through #6 only).  This exercise test will be completed on a stationary 
bicycle.  You will be asked to complete 3 separate cycle exercise efforts lasting 3 minutes each, separated by 10 minutes 
of seated rest.  Each of the cycle exercise efforts will be at progressively higher resistances, equal to 25%, 50%, and 75% 
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of the peak resistance you achieved in the maximal cycle test.  For each of the 3 cycle exercise efforts, resting 
measurements will be collected for 5 minutes and followed by a 5 minute warm-up at a very light resistance.  You will be 
able to view a screen that shows the time completed.   
 
All of the exercise tests (maximal cycle exercise, forearm handgrip, and submaximal cycle exercise) include wearing a 
clip that shines light through your index finger, either adhesive electrodes on your chest or a wireless heart rate monitor 
strap, and breathing either through a rubber mouthpiece while wearing nose clips, or a face mask which covers your nose 
and mouth.  Either room air or low oxygen air simulating an altitude of approximately 9,900ft will flow into and out of 
your lungs as you breathe through the mouthpiece or face mask. You will not be told which air (room air or low oxygen 
air) you will be given.  Rubber mouthpieces, face masks, heart rate monitor, and nose clips are cleansed in a detergent and 
antibacterial solution following each use.   During each forearm exercise test, a fiber optic cable bundle will be secured by 
elastic bandages to your exercising forearm (about 1/3
rd
 of the distance from your elbow to your wrist).  During the 
submaximal cycle exercise test, a fiber optic cable bundle will be secured by elastic bandages to your left thigh and left 
calf.  This device uses light waves to measure the oxygen content of your tissues. 
 
Finger prick blood samples.  Prior to the first exercise effort and immediately after each exercise effort of the forearm 
handgrip and submaximal cycle exercise test, we will prick your fingertip with a sterile needle and collect a few drops of 
blood.  This means on each of Visits #3 through #6, you will receive a total of 8 finger pricks. 
  
 
RISKS OF TAKING PART IN THE STUDY: 
 
While on the study, the risks are: 
 
Both maximal and moderate level exercise tests of healthy individuals, as described by the American College of Sports 
Medicine, presents little risk to the subject and does not require medical clearance for subjects under 40.  For untrained 
and type 2 diabetic subjects, men over 45 years of age and women over 55 years of age, the risks associated with exercise 
testing increases.  Potential risks and/or discomforts can include episodes of temporary light-headedness, chest 
discomfort, leg or arm cramps, occasional irregular heartbeats, and abnormal blood pressure responses.  The risk of heart 
attack, although minor, (approximately 1 to 2 in 10,000) does exist, and a heart attack could result in death.  During 
exercise testing you will be closely monitored for any abnormal changes in heart rate or breathing.  You are free to 
indicate any discomfort and discontinue participation at any time. 
 
There is a slight risk of skin discomfort or irritation from the fiber optic bundles and electrodes that will be placed on your 
skin.  
 
There is a risk of blood pooling in your legs and low blood pressure immediately following the cycle exercise tests.  After 
the tests, you will be allowed to cool down on the exercise bike.  If at any time during testing you become light headed, 
you may have to lie down until you feel normal. 
 
Risks associated with taking blood include excessive bleeding, fainting or feeling lightheaded, and possible infection.  All 
blood samples will be taken by qualified individuals.  A reasonable effort will be made to minimize the risks associated 
with drawing blood through the use of proper procedures and sterile techniques.   
 
Potentially negative side effects could occur while taking the supplements.  Common side effects include vomiting, 
nausea, bloating and burping. Rare side effects consist of easy bleeding/bruising and serious allergic reaction. 
 
Breathing low oxygen air involves the risk of lightheadedness, heavy breathing, dry throat, and irritation of nasal passages 
due to the dry nature of the gas used. 
 
In type 2 diabetic subjects, there is a risk of hypoglycemia (low blood sugar).  
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There is a potential risk of loss of confidentiality. 
 
 
BENEFITS OF TAKING PART IN THE STUDY: 
 
The benefits to participation that are reasonable to expect are information regarding your cholesterol and glucose levels, 
overall level of fitness, and how omega-3 fatty acid (fish oil) supplements may help you tolerate exercise better.  Other 
than this information, you will gain little benefit.  All subjects will be provided with feedback concerning their own results 
and the general findings of the study upon request. 
 
CONFIDENTIALITY 
 
Efforts will be made to keep your personal information confidential.  Data will be stored on password protected computers 
in locked rooms with limited public access.  We cannot guarantee absolute confidentiality.  Your personal information 
may be disclosed if required by law.  Your identity will be held in confidence in reports in which the study may be 
published and databases in which results may be stored. 
 
Organizations that may inspect and/or copy your research records for quality assurance and data analysis include groups 
such as the study investigator and his/her research associates, the American Diabetes Association, the IU Institutional 
Review Board or its designees, and (as allowed by law) state or federal agencies, specifically the Office for Human 
Research Protections (OHRP) and the U.S. Food and Drug Administration (FDA), who may need to access the collected 
medical and/or research data. 
 
 
PAYMENT 
 
You will be paid a total of $150 for completing all (6) days of testing.  Payment will be made by check and will be 
delivered by postal mail within approximately 4 weeks of your final testing session.  If you withdraw prior to completing 
all days of testing, you will be paid according the exercise trial(s) you complete or attempt to complete; $30 per exercise 
trial (Visits 2-6).   
 
 
COMPENSATION FOR INJURY 
 
In the event of physical injury resulting from your participation in this research, necessary medical treatment will be 
provided to you at your own expense.  Costs not covered by your health care insurer will be your responsibility.  Also, it 
is your responsibility to determine the extent of your health care coverage.  There is no program in place for other 
monetary compensation for such injuries.  However, by signing this form you are not giving up any legal rights or benefits 
to which you are otherwise entitled. 
 
 
CONTACTS FOR QUESTIONS OR PROBLEMS 
 
For questions about the study or a research-related injury, contact the researcher Robert Chapman, Ph.D. at (812) 856-
2452 or rfchapma@indiana.edu.  If you cannot reach the researcher during regular business hours (i.e. 8:00AM-5:00PM), 
please call the IU Human Subjects Office at (812) 856-4242 or (800) 696-2949.   
 
For questions about your rights as a research participant or to discuss problems, complaints or concerns about a research 
study, or to obtain information, or offer input, contact the IU Human Subjects Office at (812) 856-4242 or (800) 696-
2949. 
54 
 
 
 
VOLUNTARY NATURE OF STUDY 
 
Taking part in this study is voluntary.  You may choose not to take part or may leave the study at any time.  Leaving the 
study will not result in any penalty or loss of benefits to which you are entitled.  Your decision whether or not to 
participate in this study will not affect your current or future relations with the investigators or Indiana University. 
 
Your participation may be terminated by the investigator without regard to your consent in the following circumstances: 
blood pressure, ECG, cholesterol, height and weight, or maximal exercise test results that do not meet the criteria for 
inclusion in the study, an abnormal response to exercise testing, or an inability to complete the exercise tests. 
 
 
SUBJECT’S CONSENT 
 
In consideration of all of the above, I give my consent to participate in this research study.   
 
I will be given a copy of this informed consent document to keep for my records.  I agree to take part in this study. 
 
 
Subject’s Printed Name:________________________________________________ 
 
Subject’s Signature:____________________________________________________Date:  
(must be dated by the subject) 
 
 
 
Printed Name of Person Obtaining Consent:  
 
Signature of Person Obtaining Consent: Date:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For IRB Office Use ONLY 
 
IRB Approval Date:  
 
Expiration Date:  
55 
 
Appendix E: Modified Physical Activity Readiness Questionnaire (PARQ) 
Modified Physical Activity Readiness Questionnaire (PAR-Q) 
Name Date 
DOB Age Home Phone Work Phone 
Regular exercise is associated with many health benefits, yet any change of activity may increase the risk of injury. Please 
read each question carefully and answer every question honestly: 
Yes No 
1. Has your doctor ever said that you have a heart condition and that you should only do physical 
activity recommended by a doctor? 
Yes No 2. Do you feel pain in your chest when you do physical activity? 
Yes No 3. In the past month, have you had chest pain when you were not doing physical activity? 
Yes No 4. Do you lose your balance because of dizziness or do you ever lose consciousness? 
Yes No 
5. Do you have a bone or joint problem that could be made worse by a change in your physical 
activity? 
Yes No 
6. Is your doctor currently prescribing drugs (for example, water pills) for your blood pressure or 
heart condition? 
Yes No 7. Do you know of any other reason you should not do physical activity? 
Yes No 8. Has your doctor ever told you that you have diabetes?  
Yes No 9. Has your doctor ever told you that you have high blood pressure?  
Yes No 10. Has your doctor ever told you that you have high cholesterol?  
Yes No 11. Has your doctor ever told you that you have high blood sugar?  
Yes No 12. Do you smoke? 
Yes No 13. Are you currently inactive?  
Yes No 
14. Do you have a father, brother or son with heart disease before the age of 55 years old or a 
mother, sister or daughter with heart disease before the age of 65 years old? 
15. Measure height and weight to determine BMI:        16. Measure resting BP and pulse 
Height:________                                                                 BP:_______________  Pulse:____________ 
Weight:________                                                           
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Participant Signature Date 
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Appendix F: General Study Questionnaire 
General Study Questionnaire 
Name Date 
On average over the last 8 weeks, how many minutes per 
week did you exercise? 
Do you consider yourself to be a highly endurance trained 
individual? 
(Circle one)  YES  NO 
Participant Signature Date 
Food Frequency Questionnaire from: Hanson JA, Lin Y, Strandjord SE, and Hibbeln JR. The Relationship between Omega-3 HUFA Score and Dietary Intake of EPA and DHA among 
U.S. Soldiers. Journal of the Academy of Nutrition and Dietetics 113: A26, 2013 
Omega-3 Food Frequency Questionnaire 
Department of Kinesiology 
Human Performance Laboratory 
Indiana University 
Appendix G: Omega-3 Food Frequency Questionnaire 
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Food Frequency Questionnaire from: Hanson JA, Lin Y, Strandjord SE, and Hibbeln JR. The Relationship between Omega-3 HUFA Score and Dietary Intake of EPA and DHA among 
U.S. Soldiers. Journal of the Academy of Nutrition and Dietetics 113: A26, 2013 
Instructions: 
This questionnaire is about how much and how often you ate foods containing high levels of omega-3 fatty acids.  It is also about how much and 
how often you consume different beverages. When answering, think about what you usually ate and drank during the last six months. Please 
remember to include foods you ate in restaurants, as takeout food, and fish you or someone you know caught.  Complete PARTS 1-3. 
Part 1 Instructions: 
Step 1: Mark the column with an “X” to show how often on average you ate the food. 
Step 2: Mark your usual serving size with an “X”, as small (S), medium (M), or large (L). 
Please note: 
• A small serving is about one-half (1/2) the medium serving size, or less.
• A large serving is about one-and-a half (1 ½) times the medium serving size or more.
• If you never ate a food, mark “never” and omit the serving size.
• Please do not skip any foods or leave blanks.
• 4 ounces of cooked fish looks like the picture on the right :
Example: This person never ate sushi, but ate a medium serving of baked or broiled white fish once a week. 
NEVER or 
less than 
once per 
month 
1 per 
month 
2-3
per
month
1
per 
week 
2
per 
week 
3-4
per
week
5-6
per
week
1
per 
day 
2 + 
per day 
Medium 
Serving 
size 
S M L 
Sushi X 1 roll 
Baked or broiled white fish 
(such as snapper, cod, halibut, 
sole) 
X 4 ounces X 
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Food Frequency Questionnaire from: Hanson JA, Lin Y, Strandjord SE, and Hibbeln JR. The Relationship between Omega-3 HUFA Score and Dietary Intake of EPA and DHA 
among U.S. Soldiers. Journal of the Academy of Nutrition and Dietetics 113: A26, 2013 
PART 1 
How often did you eat these foods during the last 6 months? 
NEVER or 
less than 
once per 
month 
1 per 
month 
2-3
per
month
1
per 
week 
2
per 
week 
3-4
per
week
5-6
per
week
1
per 
day 
2 + 
per day 
Medium 
Serving 
size 
S M L 
Canned tuna, tuna salad, tuna 
sandwich, tuna casserole 
1 can or 
1 cup 
casserole 
Fried fish, fish sandwich, 
fish sticks 
4 ounces 
or 1 
sand- 
witch 
Shellfish (shrimp, clams, 
oysters,  lobster, crayfish) 
4 ounces 
Sardines 1 can 
Baked, broiled, or grilled white 
fish (such as snapper, cod, 
halibut, sole) 
4 ounces 
Baked, broiled, or grilled dark 
or oily fish (such as salmon, 
mackerel, and bluefish) 
4 ounces 
Sushi 
Please write type 
2 rolls 
Beef 4 ounces 
Pork 4 ounces 
Dark chicken meat 2 pieces 
Eggs with yolks 2 egg 
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PART 2 
See the display for examples of foods enriched with DHA and/or other omega-3 fatty acids.  Did you eat any DHA or omega-3 enriched foods 
during the last 6 months? (Circle) YES or  NO 
If  NO skip to Part 3.  If YES, write in: 1) the food, 2) your usual serving size, and 3) how often eaten. 
Food Usual Serving Size NEVER or 
less than 
once per 
month 
1 per 
month 
2-3
per
month
1
per 
week 
2
per 
week 
3-4
per
week
5-6
per
week
1
per day 
2 + 
per day 
Example : 
Horizon DHA milk 8 oz X 
Food Frequency Questionnaire from: Hanson JA, Lin Y, Strandjord SE, and Hibbeln JR. The Relationship between Omega-3 HUFA Score and Dietary Intake of EPA and 
DHA among U.S. Soldiers. Journal of the Academy of Nutrition and Dietetics 113: A26, 2013 
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6163 
PART 3 
Did you take any nutritional supplements during the last 6 months? (Circle) Yes or No 
If NO, skip to end. If YES, how much and how often? 
Supplement How much did you normally take? 
Cod liver oil, fish oil, or omega -3 supplements 
1. 
Please Specify 
1.  
2. 
2.  
Multivitamin 
1. 
Please Specify 
1.  
2. 
2.  
Other vitamin, mineral or nutritional supplements 
1. 
Please Specify 
1.  
2. 
2.  
END 
Food Frequency Questionnaire from: Hanson JA, Lin Y, Strandjord SE, and Hibbeln JR. The Relationship between Omega-3 HUFA Score and Dietary Intake of EPA and 
DHA among U.S. Soldiers. Journal of the Academy of Nutrition and Dietetics 113: A26, 2013 
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